Celularity Inc. (CELU)

From the record

Celularity Inc.'s filings since 2018 show 25 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 10 times, the latest 2026-07-29); a warning not to rely on past financial statements (8-K item 4.02, the latest 2021-04-30); an auditor change (8-K item 4.01, 2 times, the latest 2024-08-05); a late-report notice (Form NT 10-K or NT 10-Q, 12 times, the latest 2026-08-14) (its current reports).

From the record

Celularity Inc.'s 6 filed years say what it did: revenue went from $14 million in fiscal 2020 to $27 million in fiscal 2025, up 13.2% a year; it rose in 3 of 5 years; the deepest fall was 51% from fiscal 2024 to fiscal 2025; net income was positive in 1 of 6 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Celularity Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 6 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 135 cents per dollar of assets, and net share issuance: its share count grew 16.9% over the year (the filed statements).

From the record

Celularity Inc.'s standing among 315 graded names in its industry family: revenue of $27 million in fiscal 2025 ranks in the bottom 49% by size; a net margin of -345.4% ranks in the bottom 41%; revenue growth of 13.9% a year over the last 3 filed years ranks in the top 43% (its annual reports).

From the record

Celularity Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Hariri, Robert J (Chief Executive Officer, as filed), filing under that title since 2021-07-16, 5.3 years (top 47% of its family); the 8 officers and directors filing in the last fifteen months have been on the record a median of 4.9 years (bottom 33%); 18 officer or director changes were reported on Form 8-K since 2023-11-13, against the 8 people in charge now (bottom 2%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Celularity Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $6 million against debt of $34 million leaves -25.7% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is -49.9% of revenue (top 44%); a gross margin of 24.4% (bottom 14%); research spending of 56.6% of revenue (bottom 44%) (its annual report).

From the record

Celularity Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 13.9% a year over the last three filed years against 13.2% over all 6, speeding up (top 28% of its family); the newest year grew -51.1% (bottom 15%); research spending grew -42.3% a year (bottom 6%); capital spending grew -70.4% a year (bottom 6%) (its annual reports). Celularity Inc. reported 3 lines of business in fiscal 2025: Degenerative Disease at $17 million (65%), Biobanking at $5 million (21%), Cell Therapy at $4 million (14%); 2 of 3 grew against the year before (its annual report).

From the record

Celularity Inc.'s newest year against its own record: revenue of $27 million in fiscal 2025 came in 71.8% below the $94 million its prior three years' pace pointed to (bottom 11% of its family); net income of $92 million against a prior three-year average of $80 million (bottom 36%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 22%) (its annual reports).